The Changing Medtech Landscape: The Rise of Reimbursement, An Interview with Mark Leahey

article image

In the first of a two-part article, MDMA’s Mark Leahey discusses the progress being made with industry’s relationships with FDA and CMS, and how reimbursement has replaced regulatory as the biggest challenge facing medtech companies.

As he enters his eighteenth year as president and CEO of the Medical Device Manufacturers Association (MDMA), the Washington, DC-based trade group that focuses on small and mid-sized medtech companies, Mark Leahey is the first to acknowledge that he has seen major shifts in many elements of the industry/government landscape.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: